Literature DB >> 10065402

Methylphenidate treatment for bulimia nervosa associated with a cluster B personality disorder.

M S Sokol1, N S Gray, A Goldstein, W H Kaye.   

Abstract

OBJECTIVES: Psychotherapy and antidepressant medication are helpful to many patients with bulimia nervosa (BN). However, a substantial number of bulimics respond poorly to such treatments. Recent studies suggest that many of the poor responders have cluster B personality disorders. In some ways, the symptomatology of bulimics who have a comorbid cluster B disorder resembles that of patients with attention deficit hyperactivity disorder (ADHD). In particular, individuals in both groups frequently have a high level of impulsivity. Such a resemblance raised the question of whether administration of methylphenidate (MPH), a drug used to treat ADHD, would have therapeutic effects in this subgroup of BN patients.
METHODS: In a pilot study, we administered MPH to 2 patients with BN and cluster B traits and found beneficial effects. These patients had not responded to adequate trials of psychotherapy and selective serotonin reuptake inhibitors (SSRIs).
RESULTS: MPH treatment was effective. Both Patients had decreased binging and purging. DISCUSSION: MPH may be useful for bulimics with cluster B personality disorder who respond poorly to conventional treatment. Further studies of MPH administration may be worthwhile. Due to the potential risks, however, clinical treatment with this agent is not recommended at this time.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065402     DOI: 10.1002/(sici)1098-108x(199903)25:2<233::aid-eat14>3.0.co;2-2

Source DB:  PubMed          Journal:  Int J Eat Disord        ISSN: 0276-3478            Impact factor:   4.861


  16 in total

Review 1.  Attention-deficit/hyperactivity disorder and its comorbidities in women and girls: an evolving picture.

Authors:  Patricia O Quinn
Journal:  Curr Psychiatry Rep       Date:  2008-10       Impact factor: 5.285

2.  Childhood onset neuropsychiatric disorders in adult eating disorder patients. A pilot study.

Authors:  Elisabet Wentz; J Hubert Lacey; Glenn Waller; Maria Råstam; Jeremy Turk; Christopher Gillberg
Journal:  Eur Child Adolesc Psychiatry       Date:  2005-12       Impact factor: 4.785

3.  Symptoms of attention deficit hyperactivity disorder in severely obese women.

Authors:  J P Fleming; L D Levy; R D Levitan
Journal:  Eat Weight Disord       Date:  2005-03       Impact factor: 4.652

Review 4.  Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Francisco Romo-Nava
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

Review 5.  Stimulant drugs.

Authors:  P J Santosh; E Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 6.  Co-existing disorders in ADHD -- implications for diagnosis and intervention.

Authors:  Christopher Gillberg; I Carina Gillberg; Peder Rasmussen; Björn Kadesjö; Henrik Söderström; Mania Råstam; Mato Johnson; Aribert Rothenberger; Lena Niklasson
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

Review 7.  Wake-promoting pharmacotherapy for psychiatric disorders.

Authors:  Bernardo Dell'Osso; Cristina Dobrea; Laura Cremaschi; Chiara Arici; A Carlo Altamura
Journal:  Curr Psychiatry Rep       Date:  2014-12       Impact factor: 5.285

Review 8.  The role of cognitive deficits in the development of eating disorders.

Authors:  Suji M Lena; Alexandra J Fiocco; JoAnna K Leyenaar
Journal:  Neuropsychol Rev       Date:  2004-06       Impact factor: 7.444

9.  The Comorbidity of ADHD and Eating Disorders in a Nationally Representative Sample.

Authors:  Jennifer R Bleck; Rita D DeBate; Roberto Olivardia
Journal:  J Behav Health Serv Res       Date:  2015-10       Impact factor: 1.505

10.  Adjunctive Methylphenidate in the Treatment of Bulimia Nervosa Co-occurring with Bipolar Disorder and Substance Dependence.

Authors:  Anna I Guerdjikova; Susan L McElroy
Journal:  Innov Clin Neurosci       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.